NEW DELHI: Panacea Biotec and Russia’s sovereign wealth fund, Russian Direct Investment Fund (RDIF) announced the start of production of the Sputnik V vaccine.
The commercial manufacture will be starting in summer. Under a tie-up, RDIF and Panacea have agreed to produce 100 million doses per year of the vaccine. Efficacy of Sputnik V is 97.6%.